- Home
- UHAL vs HALO Comparison
UHAL vs HALO Comparison
Compare UHAL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHAL | HALO |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | United States | United States |
| Employees | 35100 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.1B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | UHAL | HALO |
|---|---|---|
| Price | $70.91 | $82.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $78.64 |
| AVG Volume (30 Days) | 159.3K | ★ 1.6M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $5.89 | $28.24 |
| Revenue Next Year | $4.41 | $12.56 |
| P/E Ratio | $78.63 | ★ $68.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.95 | $58.68 |
| 52 Week High | $74.01 | $84.44 |
Technical Indicators
Market Signals| Indicator | UHAL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 64.22 |
| Support Level | $48.91 | $62.21 |
| Resistance Level | $72.95 | N/A |
| Average True Range (ATR) | 1.75 | 2.17 |
| MACD | -0.39 | 0.22 |
| Stochastic Oscillator | 40.27 | 80.43 |
Price Performance
Historical ComparisonAbout UHAL U-Haul Holding Company
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.